Cargando…

Mechanisms of action, efficacy, and safety of icosapent ethyl: from bench to bedside

Detalles Bibliográficos
Autor principal:	Bhatt, Deepak L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537798/ https://www.ncbi.nlm.nih.gov/pubmed/33061863 http://dx.doi.org/10.1093/eurheartj/suaa114

Ejemplares similares

Clinical results and mechanism of action of icosapent ethyl
por: Borghi, Claudio, et al.
Publicado: (2023)

Efficacy and safety of icosapent ethyl in hypertriglyceridaemia: a recap
por: Parhofer, Klaus G, et al.
Publicado: (2020)

The reduction in cardiovascular risk in REDUCE-IT is due to eicosapentaenoic acid in icosapent ethyl
por: Steg, Ph Gabriel, et al.
Publicado: (2021)

Beyond cardiovascular medicine: potential future uses of icosapent ethyl
por: Bhatt, Deepak L, et al.
Publicado: (2020)

The Road to Approval: a Perspective on the Role of Icosapent Ethyl in Cardiovascular Risk Reduction
por: Wang, Xiaowen, et al.
Publicado: (2020)

Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses
por: Peterson, Benjamin E., et al.
Publicado: (2020)

Icosapent ethyl for the treatment of severe hypertriglyceridemia
por: Fares, Hassan, et al.
Publicado: (2014)

Icosapent ethyl: scientific and legal controversies
por: Curfman, Gregory, et al.
Publicado: (2021)

Potential effects of icosapent ethyl on cardiovascular outcomes in cigarette smokers: REDUCE-IT smoking
por: Miller, Michael, et al.
Publicado: (2022)

Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE‐IT
por: Selvaraj, Senthil, et al.
Publicado: (2022)

Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE‐IT
por: Olshansky, Brian, et al.
Publicado: (2023)

Rationale and design of REDUCE‐IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial
por: Bhatt, Deepak L., et al.
Publicado: (2017)

A randomized trial of icosapent ethyl in ambulatory patients with COVID-19
por: Kosmopoulos, Andrew, et al.
Publicado: (2021)

The potential population health impact of treating REDUCE-IT eligible US adults with Icosapent Ethyl
por: Derington, Catherine G., et al.
Publicado: (2022)

Icosapent Ethyl (Vascepa®) for the Treatment of Acute, Severe Pancreatitis
por: Berger, Amnon A, et al.
Publicado: (2020)

Effect of Concomitant Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on the Pharmacokinetics of Atorvastatin
por: Braeckman, Rene A., et al.
Publicado: (2014)

Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment
por: Weintraub, William S., et al.
Publicado: (2022)

The Novelty of Icosapent Ethyl in the Management of Hypertriglyceridemia and Alleviating Cardiovascular Risk
por: Khan, Muhammad Shoaib, et al.
Publicado: (2021)

A Critical Review of Icosapent Ethyl in Cardiovascular Risk Reduction
por: Huston, Jessica, et al.
Publicado: (2023)

Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE)
por: Ambrosy, Andrew P., et al.
Publicado: (2021)

Takotsubo Syndrome: From Bench to Bedside and Bedside to Bench
por: Pelliccia, Francesco, et al.
Publicado: (2022)

Spotlight on Icosapent Ethyl for Cardiovascular Risk Reduction: Evidence to Date
por: Jia, Xiaoming, et al.
Publicado: (2020)

Potential Benefits of Icosapent Ethyl on the Lipid Profile: Case Studies
por: Hilleman, Daniel E., et al.
Publicado: (2014)

Benefit of icosapent ethyl on coronary physiology assessed by computed tomography angiography fractional flow reserve: EVAPORATE-FFR(CT)
por: Rabbat, Mark G, et al.
Publicado: (2023)

From bench to bedside
por: Verdant, Colin L
Publicado: (2012)

Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Pharmacokinetic Parameters of Rosiglitazone in Healthy Subjects
por: Braeckman, Rene A, et al.
Publicado: (2015)

Effectiveness of icosapent ethyl on first and total cardiovascular events in patients with metabolic syndrome, but without diabetes: REDUCE-IT MetSyn
por: Miller, Michael, et al.
Publicado: (2023)

Effect of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Omeprazole Plasma Pharmacokinetics in Healthy Adults
por: Braeckman, Rene A., et al.
Publicado: (2014)

Icosapent Ethyl – A Successful Treatment for Symptomatic COVID-19 Infection
por: Berger, Amnon A, et al.
Publicado: (2020)

Cardiovascular Risk Reduction With Icosapent Ethyl: A Systematic Literature Review
por: Thakur, Mala, et al.
Publicado: (2020)

Emphasis on Icosapent Ethyl for Cardiovascular Risk Reduction: A Systematic Review
por: Sutariya, Bansi, et al.
Publicado: (2022)

Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial
por: Budoff, Matthew J, et al.
Publicado: (2020)

Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL
por: Majithia, Arjun, et al.
Publicado: (2021)

Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE‐IT PCI
por: Peterson, Benjamin E., et al.
Publicado: (2022)

Lung Mechanics Over the Century: From Bench to Bedside and Back to Bench
por: Biselli, Paolo Jose Cesare, et al.
Publicado: (2022)

Three Cases of COVID-19 Pneumonia That Responded to Icosapent Ethyl Supportive Treatment
por: Suh, Winston, et al.
Publicado: (2020)

Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics
por: Boden, William E, et al.
Publicado: (2020)

Bench and Bedside
por: Schmidt, Christian
Publicado: (2002)

Global eligibility and cost effectiveness of icosapent ethyl in primary and secondary cardiovascular prevention
por: Toth, Peter P., et al.
Publicado: (2023)

Bench-to-bedside review: Amelioration of acute renal impairment using ethyl pyruvate
por: Reade, Michael C, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_v0c1iifkep403t25118s8p0mmm